v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

A CROSS-SECTIONAL RESEARCH TO EVALUATE INSULIN RESISTANCE AMONG THE PATIENTS OF CHRONIC KIDNEY DISEASE (CKD)

AUTHORS:

Dr Fazal Abbas Haider, Dr Shanza Naeem, Dr Ifrah Jabbar

ABSTRACT:

Objective: The objective of this research study was to evaluate insulin resistance among CKD patients. Patients and Methods: This cross-sectional research was carried out on a total of 50 patients being treated for structural renal abnormalities or deranged renal functions at Jinnah Hospital, Lahore (February 2019 to January 2020). All the recruited patients did not show any dialysis or diabetes history. Another fifty healthy controls were also included in the research of the same age group. All the patients were screened for lipid profile, renal function tests, complete blood count (CPC), serum insulin levels and fasting plasma glucose. HOMA-IR method was used for the calculation of insulin resistance. We made a statistical analysis of research outcomes on SPSS software. Results: We enrolled controls and cases having fifty in each group. Males dominated females in number in cases. Total of 34% of the cases were females; whereas, 66% were males. On the other hand, in controls 26% were females and 74% were males. The mean age of controls and cases was respectively (49 ± 9) years and (50 ± 10) years. CKD patients showed higher levels of fasting insulin and significantly higher HOMA-IR in comparison to controls (P-Value 0.001). The lipid profile showed a significant difference in the levels of triglycerides in statistical analysis. Conclusion: HOMA-IR was significantly higher among CKD patients which clearly shows an association between insulin resistance and CKD. Keywords: Insulin Resistance, CKD, HOMA-IR, and Hypertriglyceridemia.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.